Lighthouse Pharmaceuticals receives a $49.2 million grant from the National Institute on Aging, aimed at advancing a Phase 2 ...

Dawnzera is the first and only RNA-targeted prophylactic therapy to be approved for hereditary angioedema in adults and ...

The agreement values Mural Oncology at up to $36.2 million, with shareholders set to receive a base cash payment and ...

Regeneron Pharmaceuticals announced FDA extended review timelines to Q4 2025 for two regulatory submissions related to Eylea ...

The collaboration will leverage Boehringer Ingelheim’s manufacturing expertise to accelerate AnGes’ HGF gene therapy toward ...

In a joint statement, 1 the White House and the EU announced the details of what is being called a framework for an agreement ...

Darzalex Faspro's supply and availability remain unaffected, and no new clinical studies were requested by the FDA.

As HHS Secretary, Kennedy cut nearly $500 million in funding for mRNA vaccine research. While he says that the decision was made after looking at the science, health experts have heavily criticized ...

Rob Abbott, CEO, ISPOR, highlights how uniting regulators, payers, and academic leaders worldwide can accelerate access to ...

Pharm Exec unveils its new slate of rising leaders in the biopharma industry—profiling the stories of five executives ...

The clinical hold is due to questions about BX004’s nebulizer device, temporarily pausing US enrollment in the cystic ...

The regulatory body determined that PTC Therapeutics’ New Drug Application for vatiquinone did not provide sufficient ...